Trevigen, a provider of products for the study of DNA damage and cancer cell behaviour, has announced that it is the primary recipient of a NIGMS, two-year Phase 2 Grant for USD2.5m (GBP1.6m).
Conducted in partnership with the University of Pittsburgh, this is a continuation of a Phase I, NIH-funded project, in which 11 different DNA Glycosylase enzyme-deficient human cell lines were developed.
The goal is to produce more than 150 DNA repair gene knockdown cell lines.
The cell lines will be made available to cancer researchers investigating genomic instability and genotoxic stress.
The DNA repair knockdowns constructs will be placed in a human glioblastoma and a human breast cancer cell line.
Each cell line and control will be stressed and the impact of the knockdown gene on the global transcriptome will be measured.
